ADNI-Validated · Research Use Only
MCI Due to Alzheimer's DiseaseDecision Support Tool
A multi-stage AI pipeline — clinical screening, parallel MRI neurodegeneration gating and plasma biomarker triage — built on ADNI data to stratify progression risk and guide next clinical steps.
* This tool is intended for research purposes only and is not approved for clinical diagnosis or treatment decisions.
Platform Architecture
Longitudinal Multimodal Brain Health Intelligence
Clinovia integrates clinical cognition, plasma biomarkers, and MRI neurodegeneration analysis into a longitudinal multimodal risk stratification pipeline.
Clinical Progression Screening
Estimates 24-month cognitive progression risk using structured clinical and neuropsychological variables.
Feature Importance
Inputs
- Demographics and education
- APOE ε4 status
- MMSE
- ECog functional measures
- RAVLT memory performance
Outputs
- 24-month progression probability
- Risk stratification
- Confidence score
- Explainability insights
Plasma Biomarker Intelligence
Estimates amyloid-associated neurodegenerative risk using blood biomarkers and clinical covariates.
Feature Importance
Inputs
- Plasma Aβ42/40 ratio
- Plasma pTau217
- GFAP
- NfL
- Clinical covariates
Outputs
- Amyloid probability score
- Risk band classification
- PET triage recommendation
- Biomarker explainability
MRI Neurodegeneration Analysis
Characterizes structural neurodegeneration using MRI volumetrics and longitudinal atrophy trajectories.
Feature Importance
Inputs
- Hippocampal volume
- Entorhinal volume
- Ventricular expansion
- Whole-brain atrophy
- Longitudinal MRI trajectories
Outputs
- MRI neurodegeneration risk
- N+ classification
- Structural trajectory analysis
- Multimodal fusion input
Fusion Layer — Coming Soon
Multimodal Longitudinal Risk Fusion
Future Clinovia models will integrate cognition, plasma biomarkers, and MRI neurodegeneration trajectories into a unified longitudinal brain health intelligence layer.
Models developed using Alzheimer's Disease Neuroimaging Initiative (ADNI) data. Research use only. Not approved for clinical diagnosis or treatment decision-making.
Core Platform Features
Built for real clinical workflows — not just prediction models. Each feature supports physician decisions, documentation, and faster treatment readiness.
Clinical Summary Report
- • Physician-ready PDF with calibrated amyloid likelihood and confidence band
- • SHAP-style feature contribution analysis for explainable clinical review
- • Longitudinal patient trajectory tracking across visits and stages
4-Tier Risk Stratification
- • Watch, Concern, High Risk, and Urgent clinical action tiers
- • Removes ambiguity by linking prediction output to concrete next steps
- • Supports faster referral decisions and standardized care pathways
PET Value Simulator
- • Determines whether confirmatory amyloid PET is likely to change management
- • Balances amyloid probability, uncertainty, and clinical stage
- • Visual PET utility dial instead of unnecessary numeric complexity
Treatment Pathway Router
- • Routes patients to the next clinical step based on tier and disease stage
- • Aligned with local reimbursement workflows and referral pathways
- • Reduces administrative friction that delays specialist referrals
Patient Communication Generator
- • Generates physician-reviewed plain-language patient summaries
- • Family-centered and non-alarming communication tailored to risk tier
- • Concrete lifestyle and follow-up recommendations for better adherence
Safety Override Layer
- • Flags uncertainty, discordant biomarkers, and atypical presentations
- • Escalates unsafe or ambiguous cases for specialist review
- • Preserves physician trust through transparent override logic
Join the Clinical Pilot Program
Partner with Clinovia.ai to bring structured, explainable Alzheimer's diagnostics into real clinical practice — from early screening through PET optimization and treatment readiness.
Designed for hospitals, memory clinics, and neurology practices, the pilot evaluates Clinovia across the full diagnostic pathway: plasma biomarker triage, MRI gating, referral timing, and physician-ready reporting — measured by real workflow adoption, not just model metrics.
Physician Adoption
Explainable outputs, physician-ready reports, and specialist-safe escalation logic built for clinical trust.
Operational ROI
Reduce unnecessary PET orders, accelerate referrals, and improve DMT candidate identification.
Clinical Workflow Integration
Adaptable to local diagnostic pathways, referral structures, and institutional reporting requirements across healthcare systems.
Seeking Validation Collaborators
We are actively partnering with clinical researchers for both retrospective validation — applying Clinovia's models to existing cohort data — and external validation across independent sites and populations.
If you are a researcher with access to relevant imaging, biomarker, or longitudinal Alzheimer's datasets and are interested in co-authorship or collaborative validation studies, we welcome your inquiry.
Ready to explore Clinovia.ai?
Early access is free — join researchers and clinical teams testing our neurology tools.
Request Early Access